Aging, Healthy
Conditions
Keywords
healthspan, healthy aging, mobility, cognitive function
Brief summary
This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.
Detailed description
This study will be a Phase 2a, open-label, single-arm study enrolling older adults subjects with lower function. The primary objective of this study is to evaluate the safety and tolerability of elamipretide, given as daily subcutaneous injection over 4 weeks. Secondary endpoints will test whether the administration of elamipretide results in changes in blood biomarkers of inflammation and improved cognitive and mobility functional performance in an older adult population. This study will be conducted in strict compliance with the protocol, current Good Clinical Practice (GCP) and all Food and Drug Administration (FDA) guidelines.
Interventions
DRUGElamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Primary Study Objective To evaluate the safety and tolerability of daily subcutaneous injections of elamipetide for 4 weeks in adults aged 65-80 Secondary Objective To assess inflammatory biomarker changes with 4-week daily injection of elamipetide on healthy aging To assess the skeletal muscle health in older subjects with lower aerobic capacity (cardiovascular health) To assess cognitive function changes with 4-week SC daily injection of elamipetide
Sponsors
Stealth BioTherapeutics Inc.
David Marcinek
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female aged ≥65 and ≤80 years 2. VO2peak ≤ 37.3ml/kg/min for men and ≤ 25.7ml/kg/min for women as evidence of lower mitochondrial function 3. Are ambulatory and able to perform activities of daily living without assistance 4. Have sufficient venous access for clinical blood draw 5. Willing and able to self-administer injections or have a willing caregiver who is able to administer injections. 6. Speak and read English 7. Have no established daily exercise routine and are not participating in any exercise training program or physical hobby (i.e. dance, martial arts, yoga) and agree to not start any such activities during the course of study participation 8. Willing to avoid the following medications during the course of the study: Anti-seizure medications * Coenzyme Q10, creatine, L-carnitine, and other supplements intended to increase muscle mass, energy or function * Muscle relaxants * Systemic steroid or immunosuppressive use * Opioids (regular use of \> 10 mg/day morphine equivalents) 9. No known allergies/adverse effects from Fexofenadine 10. Provide documentation of informed consent
Exclusion criteria
1. Have significant disease(s) or condition(s) which, in the opinion of the investigator, may put the subject at risk because of their participation in the study or may influence either the results of the study or the subject's ability to participate in the study 2. Presence of severe renal disease (eGFR \<30 mL/min) or hepatic disease (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \>2x the upper limit of normal) as evidenced by laboratory results at Screening. 3. Have a history of rhabdomyolysis 4. Have been hospitalized within 3 months prior to screening for major atherosclerotic events (e.g., myocardial infarction, target-vessel revascularization, coronary bypass surgery or stroke) or other major medical condition (as deemed by the primary investigator) 5. Are currently enrolled in a clinical study involving an investigational product or non- approved use of a drug or device or concurrently enrolled in any other type of medical research judged to be scientifically or medically incompatible with this study 6. Have participated within the last 30 days of screening visit in a clinical study involving an investigational product. \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of daily subcutaneous injections of elamipetide: Number of participants with treatment-related adverse events and Number of participants completed 4 weeks of injection | 4 week |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| blood inflammation markers | up to 5 months from first enrollment | levels of BDNF, VEGF, IGF-1, IL-6 |
| blood inflammation marker | up to 5 months from first enrollment | level of TNF-a |
| Delta 6 minute walk test | 4-6 weeks after enrollment | Change in distance walked in 6 minutes following 4 weeks of intervention |
| Delta cognitive function score | 4-6 weeks after enrollment | MoCA to access cognitive function from different domains. MoCA scale is 0-30 with scores \>26 indicating normal cognitive function. This is measured by a scale the higher means better function. Trail marking A&B time faster is better; Stroop timed test for attention, processing speed, and executive control. |
| Delta skeletal muscle strength | 4-6 weeks from enrollment | The investigators will measure the change in muscle strength on a 1 rep knee extensor assay following 4 weeks of intervention |
Countries
United States
Contacts
Primary ContactSophia Liu, PhD
Outcome results
None listed